Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

Inclusion Criteria: * Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent). * Has an ECOG performance status score of 0 or 1. * Has a life expectancy of \> 12 weeks in the opinion of the investigator. * Measurable or evaluable disease by CT/MRI according to RECIST v1.1, except for prostate and breast cancer (bone only metastases are acceptable) and glioma. * Histologically or cytologically confirmed locally advanced/metastatic solid cancers. * Has adequate organ function within 7 days prior to Day 1 of Cycle 1, defined as below: * Laboratory Value * Hematology * Platelet count \> 100 x 109/L * Hb \> 9.0 g/dL * ANC \> 1.5 x 109/L * Renal Function * Creatinine \< 1.5 x ULN * Hepatic Function * AST and ALT \< 3 x ULN for the reference laboratory or \< 5 x ULN in the presence of liver metastases * Total bilirubin ≤ 1.5 x ULN * Serum albumin ≥ 2.5 g/dL * INR/PT and APTT ≤ 1.5 x ULN * Male and female participants of reproductive/childbearing potential must agree to use adequate contraceptive methods (e.g., double barrier or intrauterine contraceptive) for at least 90 days during the study and after the last dose of study drug. * Male participants must not freeze or donate sperm starting at screening and throughout the study period, and at least 90 days after the final study drug administration. * Female participants must not donate, or retrieve for their own use, ova from the ti…